Table 30.
Country | Ampicillin | Azithromycin | Cefotaxime | Ceftazidime | Chloramphenicol | Ciprofloxacin | Colistina | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | |
2015 | ||||||||||||||
Austria | 163 | 12.9 | 163 | 0 | 163 | 2.5 | 163 | 1.8 | 163 | 3.7 | 163 | 4.9 | 163 | 0.6 |
Belgium | 186 | 35.5 | 186 | 0 | 186 | 1.1 | 186 | 1.1 | 186 | 17.7 | 186 | 2.2 | 186 | 0 |
Bulgaria | 21 | 57.1 | 21 | 4.8 | 21 | 0 | 21 | 0 | 21 | 52.4 | 21 | 47.6 | 21 | 0 |
Croatia | 85 | 32.9 | 85 | 0 | 85 | 0 | 85 | 0 | 85 | 10.6 | 85 | 7.1 | 85 | 0 |
Cyprus | 55 | 89.1 | 55 | 45.5 | 55 | 5.5 | 55 | 5.5 | 55 | 69.1 | 55 | 43.6 | 55 | 0 |
Czech Republic | 187 | 34.8 | 187 | 1.1 | 187 | 2.1 | 187 | 2.6 | 187 | 8.6 | 187 | 2.1 | 187 | 0 |
Denmark | 174 | 31.6 | 174 | 0.6 | 174 | 0 | 174 | 0 | 174 | 2.3 | 174 | 1.1 | 174 | 0.6 |
Estonia | 85 | 31.8 | 85 | 1.2 | 85 | 1.2 | 85 | 1.2 | 85 | 9.4 | 85 | 7.1 | 85 | 0 |
Finland | 217 | 14.3 | 217 | 0 | 217 | 0 | 217 | 0 | 217 | 0.9 | 217 | 0.5 | 217 | 0 |
France | 200 | 19.5 | 200 | 0.5 | 200 | 0.5 | 200 | 0.5 | 200 | 12 | 200 | 4.5 | 200 | 0 |
Germany | 212 | 33 | 212 | 2.4 | 212 | 3.3 | 212 | 3.3 | 212 | 6.6 | 212 | 4.2 | 212 | 0 |
Greece | 116 | 57.8 | 116 | 2.6 | 116 | 5.2 | 116 | 5.2 | 116 | 36.2 | 116 | 12.1 | 116 | 0 |
Hungary | 170 | 39.4 | 170 | 0.6 | 170 | 1.2 | 170 | 1.2 | 170 | 11.2 | 170 | 8.2 | 170 | 0 |
Ireland | 147 | 25.2 | 147 | 1.4 | 147 | 0.7 | 147 | 0.7 | 147 | 10.2 | 147 | 2.7 | 147 | 0 |
Italy | 168 | 63.7 | 168 | 1.8 | 168 | 0.6 | 168 | 0 | 168 | 32.7 | 168 | 14.9 | 168 | 0.6 |
Latvia | 150 | 26.7 | 150 | 0 | 150 | 0 | 150 | 0 | 150 | 8 | 150 | 5.3 | 150 | 0.7 |
Lithuania | 89 | 34.8 | 89 | 2.2 | 89 | 0 | 89 | 0 | 89 | 11.2 | 89 | 10.1 | 89 | 2.2 |
Malta | 68 | 25 | 68 | 0 | 68 | 0 | 68 | 0 | 68 | 10.3 | 68 | 5.9 | 68 | 0 |
Netherlands | 298 | 28.9 | 298 | 1 | 298 | 0.3 | 298 | 0.3 | 298 | 9.4 | 298 | 0.7 | 298 | 0 |
Poland | 170 | 35.9 | 170 | 0 | 170 | 4.1 | 170 | 4.7 | 170 | 12.4 | 170 | 15.9 | 170 | 0 |
Portugal | 198 | 74.7 | 198 | 14.6 | 198 | 5.1 | 198 | 5.1 | 198 | 52 | 198 | 20.7 | 198 | 2.5 |
Romania | 399 | 67.2 | 399 | 7.8 | 399 | 1.5 | 399 | 1.5 | 399 | 40.9 | 399 | 29.6 | 399 | 0.5 |
Slovakia | 85 | 31.8 | 85 | 1.2 | 85 | 0 | 85 | 0 | 85 | 15.3 | 85 | 7.1 | 85 | 0 |
Slovenia | 85 | 22.4 | 85 | 1.2 | 85 | 0 | 85 | 0 | 85 | 7.1 | 85 | 2.4 | 85 | 0 |
Spain | 170 | 82.4 | 170 | 2.9 | 170 | 0.6 | 170 | 0.6 | 170 | 40 | 170 | 49.4 | 170 | 2.9 |
Sweden | 200 | 20.5 | 200 | 0.5 | 200 | 1 | 200 | 0 | 200 | 3 | 200 | 2.5 | 200 | 0 |
United Kingdom | 170 | 35.3 | 170 | 1.2 | 170 | 0 | 170 | 0 | 170 | 28.2 | 170 | 2.4 | 170 | 0.6 |
Total (27 MSs) | 4,268 | 39.3 | 4,268 | 2.8 | 4,268 | 1.4 | 4,268 | 1.3 | 4,268 | 18.3 | 4,268 | 10.5 | 4,268 | 0.4 |
Norway | 270 | 11.1 | 270 | 0 | 270 | 0.7 | 270 | 0.4 | 270 | 2.2 | 270 | 0.7 | 270 | 0 |
Switzerland | 182 | 17.0 | 182 | 0 | 182 | 0.5 | 182 | 0.5 | 182 | 8.2 | 182 | 3.3 | 182 | 0 |
2014 | ||||||||||||||
Denmark | 82 | 36.6 | 82 | 0 | 82 | 0 | 82 | 0 | 82 | 2.4 | 82 | 1.2 | 82 | 0 |
Netherlands | 392 | 24.0 | 392 | 0 | 392 | 0.5 | 392 | 1.0 | 392 | 12.0 | 392 | 0 | 392 | 0 |
Total (2 MSs) | 474 | 26.2 | 474 | 0 | 474 | 0.4 | 474 | 0.8 | 474 | 10.3 | 474 | 0.2 | 474 | 0 |
Country | Gentamicin | Nalidixic acid | Sulfamethoxazole | Tetracycline | Tigecyclineb | Trimethoprim | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | |
2015 | ||||||||||||
Austria | 163 | 2.5 | 163 | 3.1 | 163 | 22.7 | 163 | 47.2 | 163 | 0 | 163 | 10.4 |
Belgium | 186 | 1.6 | 186 | 1.6 | 186 | 43.0 | 186 | 40.3 | 186 | 0 | 186 | 38.2 |
Bulgaria | 21 | 0 | 21 | 23.8 | 21 | 90.5 | 21 | 76.2 | 21 | 0 | 21 | 28.6 |
Croatia | 85 | 3.5 | 85 | 10.6 | 85 | 40.0 | 85 | 56.5 | 85 | 0 | 85 | 21.2 |
Cyprus | 55 | 21.8 | 55 | 21.8 | 55 | 98.2 | 55 | 100 | 55 | 14.5 | 55 | 94.5 |
Czech Republic | 187 | 3.2 | 187 | 1.1 | 187 | 36.9 | 187 | 48.1 | 187 | 0 | 187 | 25.1 |
Denmark | 174 | 1.1 | 174 | 0.6 | 174 | 35.6 | 174 | 35.6 | 174 | 0 | 174 | 24.1 |
Estonia | 85 | 1.2 | 85 | 4.7 | 85 | 34.1 | 85 | 41.2 | 85 | 0 | 85 | 25.9 |
Finland | 217 | 0.9 | 217 | 0.5 | 217 | 17.1 | 217 | 21.2 | 217 | 0 | 217 | 15.2 |
France | 200 | 2.0 | 200 | 4.5 | 200 | 41.0 | 200 | 54.5 | 200 | 0 | 200 | 34.5 |
Germany | 212 | 3.3 | 212 | 2.4 | 212 | 35.4 | 212 | 44.8 | 212 | 0 | 212 | 25.9 |
Greece | 116 | 3.4 | 116 | 8.6 | 116 | 64.7 | 116 | 79.3 | 116 | 0 | 116 | 56.9 |
Hungary | 170 | 2.4 | 170 | 6.5 | 170 | 30.0 | 170 | 68.2 | 170 | 0 | 170 | 17.1 |
Ireland | 147 | 2.0 | 147 | 2.0 | 147 | 44.2 | 147 | 59.2 | 147 | 0 | 147 | 36.7 |
Italy | 168 | 4.2 | 168 | 6.5 | 168 | 63.1 | 168 | 72.0 | 168 | 0 | 168 | 58.3 |
Latvia | 150 | 4.0 | 150 | 4.0 | 150 | 29.3 | 150 | 44.0 | 150 | 0 | 150 | 20.7 |
Lithuania | 89 | 3.4 | 89 | 7.9 | 89 | 43.8 | 89 | 51.7 | 89 | 0 | 89 | 29.2 |
Malta | 68 | 4.4 | 68 | 4.4 | 68 | 42.6 | 68 | 69.1 | 68 | 1.5 | 68 | 41.2 |
Netherlands | 298 | 0.7 | 298 | 0.7 | 298 | 40.3 | 298 | 45.3 | 298 | 0 | 298 | 35.9 |
Poland | 170 | 1.8 | 170 | 6.5 | 170 | 36.5 | 170 | 48.2 | 170 | 0 | 170 | 18.8 |
Portugal | 198 | 2.0 | 198 | 9.1 | 198 | 76.8 | 198 | 89.4 | 198 | 0 | 198 | 68.7 |
Romania | 399 | 9.0 | 399 | 16.0 | 399 | 63.4 | 399 | 74.2 | 399 | 0 | 399 | 47.6 |
Slovakia | 85 | 3.5 | 85 | 7.1 | 85 | 34.1 | 85 | 48.2 | 85 | 0 | 85 | 22.4 |
Slovenia | 85 | 0 | 85 | 0 | 85 | 15.3 | 85 | 40.0 | 85 | 0 | 85 | 14.1 |
Spain | 170 | 3.5 | 170 | 25.9 | 170 | 75.9 | 170 | 89.4 | 170 | 0 | 170 | 74.7 |
Sweden | 200 | 0.5 | 200 | 2.0 | 200 | 25.0 | 200 | 10.0 | 200 | 0 | 200 | 19.5 |
United Kingdom | 170 | 7.6 | 170 | 1.2 | 170 | 54.7 | 170 | 67.6 | 170 | 0 | 170 | 47.1 |
Total (27 MSs) | 4,268 | 3.3 | 4,268 | 6.0 | 4,268 | 44.2 | 4,268 | 54.7 | 4,268 | 0.2 | 4,268 | 35.3 |
Norway | 270 | 0 | 270 | 0.7 | 270 | 14.1 | 270 | 9.6 | 270 | 1.1 | 270 | 9.6 |
Switzerland | 182 | 1.6 | 182 | 3.3 | 182 | 41.8 | 182 | 29.7 | 182 | 0 | 182 | 22.0 |
2014 | ||||||||||||
Denmark | 82 | 1.2 | 82 | 1.2 | 82 | 35.4 | 82 | 41.5 | 82 | 0 | 82 | 31.7 |
Netherlands | 392 | 3.6 | 392 | 0.3 | 392 | 41.3 | 392 | 49.2 | 392 | 0 | 392 | 30.9 |
Total (2 MSs) | 474 | 3.2 | 474 | 0.4 | 474 | 40.3 | 474 | 47.9 | 474 | 0 | 474 | 31 |
All E. coli isolates tested were susceptible to meropenem. MSs: Member States; N: number of isolates tested; % Res: percentage of resistant isolates.
The reported occurrence of colistin resistance is unlikely to equate to the occurrence of mcr‐1/mcr‐2 genes.
ECOFF applied 1 mg/L.